Stock of Spruce Biosciences, Inc. (SPRB) is falling about 5 percent during Wednesday morning trading despite announcement of positive outcomes from two recent Type B meetings with the U.S. FDA regarding its planned biologics license application for tralesinidase alfa enzyme replacement therapy or TA-ERT.
The company's stock is currently trading at $54.79, down 5.93 percent or $3.45, over the previous close of $58.24 on the Nasdaq. It has traded between $7.00 and $2,508.75 in the past one year.
The company anticipates BLA Submission for TA-ERT in the fourth quarter to accommodate FDA's drug product process performance qualification requirement.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.